Zhou Shiyue, Zhao Zixuan, Zhong Hao, Ren Zehao, Li Yuye, Wang Hong, Qiu Yuling
State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Road, Jinghai District, Tianjin, 301617, People's Republic of China.
School of Medical Technology, Tianjin University of Traditional Chinese Medicine, 10 Poyanghu Rd., West Area, Tuanbo New Town, Jinghai Dist, Tianjin, 301617, China.
Discov Oncol. 2023 May 23;14(1):77. doi: 10.1007/s12672-023-00681-8.
MDSCs are immature myeloid immune cells, which accumulate in models of liver cancer to reduce effector immune cell activity, contribute to immune escape and treatment resistance. The accumulation of MDSCs suppresses the role of CTL and the killing effects of NK cells, induces the accumulation of Treg cells, and blocks the antigen presentation of DCs, thus promoting the progression of liver cancer. Recently, immunotherapy has emerged a valuable approach following chemoradiotherapy in the therapy of advanced liver cancer. A considerable increasing of researches had proved that targeting MDSCs has become one of the therapeutic targets to enhance tumor immunity. In preclinical study models, targeting MDSCs have shown encouraging results in both alone and in combination administration. In this paper, we elaborated immune microenvironment of the liver, function and regulatory mechanisms of MDSCs, and therapeutic approaches to target MDSCs. We also expect these strategies to supply new views for future immunotherapy for the treatment of liver cancer.
髓源性抑制细胞（MDSCs）是未成熟的髓系免疫细胞，在肝癌模型中会积累，以降低效应免疫细胞的活性，导致免疫逃逸和治疗抵抗。MDSCs的积累会抑制细胞毒性T淋巴细胞（CTL）的作用和自然杀伤（NK）细胞的杀伤效应，诱导调节性T细胞（Treg细胞）的积累，并阻断树突状细胞（DCs）的抗原呈递，从而促进肝癌的进展。近年来，免疫疗法已成为晚期肝癌放化疗后的一种有价值的治疗方法。大量研究已证明，靶向MDSCs已成为增强肿瘤免疫的治疗靶点之一。在临床前研究模型中，靶向MDSCs在单独给药和联合给药方面均显示出令人鼓舞的结果。在本文中，我们阐述了肝脏的免疫微环境、MDSCs的功能和调节机制以及靶向MDSCs的治疗方法。我们还期望这些策略能为未来肝癌免疫治疗提供新的思路。
